Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Stock analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Taysha Gene Therapies in a research report issued to clients and investors on Monday, May 19th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($0.36) for the year, up from their previous estimate of ($0.38). Cantor Fitzgerald currently has a "Overweight" rating and a $7.00 target price on the stock. The consensus estimate for Taysha Gene Therapies' current full-year earnings is ($0.35) per share.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.08). The company had revenue of $2.30 million for the quarter, compared to analysts' expectations of $1.48 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. During the same quarter in the prior year, the firm earned ($0.10) EPS.
A number of other research analysts have also weighed in on TSHA. Canaccord Genuity Group lifted their price objective on shares of Taysha Gene Therapies from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, May 16th. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Chardan Capital reaffirmed a "buy" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $6.57.
Get Our Latest Stock Report on TSHA
Taysha Gene Therapies Stock Performance
Shares of TSHA traded down $0.10 on Wednesday, reaching $2.75. 4,063,290 shares of the company's stock traded hands, compared to its average volume of 2,908,833. The stock has a market cap of $590.32 million, a PE ratio of 4.37 and a beta of 0.90. The stock's 50 day simple moving average is $1.83 and its two-hundred day simple moving average is $1.87. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $4.32.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in TSHA. Charles Schwab Investment Management Inc. lifted its holdings in Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock valued at $820,000 after buying an additional 11,390 shares in the last quarter. LPL Financial LLC purchased a new position in shares of Taysha Gene Therapies during the fourth quarter worth $104,000. Adage Capital Partners GP L.L.C. acquired a new position in Taysha Gene Therapies in the fourth quarter valued at approximately $8,650,000. Hsbc Holdings PLC increased its stake in shares of Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after purchasing an additional 8,076 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Taysha Gene Therapies by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company's stock valued at $15,409,000 after purchasing an additional 641,305 shares in the last quarter. Institutional investors own 77.70% of the company's stock.
About Taysha Gene Therapies
(
Get Free Report)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Featured Articles
Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
